Taiko Pharmaceutical Co.,Ltd.
大幸薬品(株)
2026/08/21 Updated
Market Cap:
$84.7M (¥13.5B)
Stock Price:
$1.69 (¥268)
Exchange Rate: 1 USD = ¥158.98
Stock Price Chart
2026/08/21 Updated14.41
PER (Price Earnings Ratio)
vs Industry Avg: +4.9
0.51
PBR (Price to Book Ratio)
vs Industry Avg: -0.8
1.31%
Dividend Yield
vs Industry Avg: -1.64%
Price Trend
2026/08/21 UpdatedShort-term
5-Day MA
-
Near-term
25-Day MA
+3.03%
Mid-term
75-Day MA
+1.12%
Long-term
200-Day MA
-5.13%
Price & Trading Details
2026/08/21 UpdatedPRICE
Previous Close
¥268
Open
¥266
High
¥268
Low
¥264
Close
¥268
TRADING
Volume
36,400
Average Volume
112,103
Turnover
¥9,755,200
Min. Purchase
¥26,800
Shareholder Composition
Updated 2026/08/0136.9%
Insider Holdings
5.6%
Institutional
57.6%
Public Float
15
Institutional Holders
Insider Holdings
36.9%
Institutional
5.6%
Public Float
57.6%
Dividend History
Updated 2026/08/23
-%
Dividend Yield
¥3
Annual Dividend
-90.6%
YoY Growth
18.0%
Payout Ratio
| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥3 | -90.6% |
| 2020 | ¥35 | +199.9% |
| 2019 | ¥12 | 0.0% |
| 2018 | ¥12 | +75.0% |
| 2017 | ¥7 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥5,040M | ¥6,120M | ¥6,292M | ¥6,397M |
| Gross Profit | ¥1,078M | ¥2,577M | ¥3,666M | ¥3,481M |
| Operating Income | -¥3,079M | -¥1,006M | ¥630M | ¥459M |
| Pretax Income | -¥4,859M | -¥3,555M | ¥573M | ¥963M |
| Net Income | -¥4,895M | -¥3,611M | ¥898M | ¥923M |
| EPS | -¥112.26 | -¥76.25 | ¥17.90 | ¥18.38 |
| Operating Margin | -61.09% | -16.44% | 10.01% | 7.18% |
| Balance Sheet | ||||
| Total Assets | ¥15,046M | ¥13,220M | ¥12,914M | ¥12,270M |
| Total Equity | ¥8,043M | ¥6,738M | ¥7,963M | ¥8,518M |
| Total Liabilities | ¥7,003M | ¥6,482M | ¥4,951M | ¥3,752M |
| Cash | ¥3,105M | ¥5,484M | ¥4,532M | ¥4,256M |
| Interest-bearing Debt | ¥3,809M | ¥3,254M | ¥2,211M | ¥970M |
| Equity Ratio | 53.46% | 50.97% | 61.66% | 69.42% |
| D/E Ratio | 0.47 | 0.48 | 0.28 | 0.11 |
| Cash Flow | ||||
| Operating CF | -¥1,994M | -¥307M | ¥362M | ¥814M |
| Investing CF | ¥190M | ¥1,166M | -¥5M | ¥142M |
| Financing CF | -¥997M | ¥1,539M | -¥1,181M | -¥1,227M |
| Free CF | -¥2,078M | -¥421M | ¥175M | ¥510M |
| Efficiency | ||||
| ROE | -60.86% | -53.59% | 11.28% | 10.84% |
| ROA | -32.53% | -27.31% | 6.95% | 7.52% |
Latest News (5 items)
Company Information
English Name
Taiko Pharmaceutical Co.,Ltd.
Japanese Name
大幸薬品(株)
Stock Code
4574.T (JPX)
Sector / Industry
Healthcare / Drug Manufacturers - Specialty & Generic
Website
https://www.seirogan.co.jp
Employees
220
About
Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines and quasi drugs in Japan and internationally. The company provides OTC medicines under the SEIROGAN, SEIROGAN TOI A and SEIROGAN Quick C, PISHUT OD Tablet brand names; and quasi-drugs under the RAPPA INTESTINAL REGULATOR BF brand names. It offers sanitation control products under the Cleverin PR, Cleverin Pro Stick, and Cleverin Pro name. In addition, the company manufactures and sells wood vinegar-based products. It exports its products. The company was incorporated in 1946 and is headquartered in Osaka, Japan.
Data provided by Yahoo Finance
